As a mage, I just want to pursue the truth

Chapter 99: Immature Scientific Creatures (Subscribe!)

This is not Li Miaomiao’s first time to come to England. She has visited Cambridge and Oxford during her high school vacation.

The feeling of coming to England this time is different from the last time. This time I came with a goal. Kechuang Biotechnology wants to acquire an AI chip company in England and build an AI chip R&D center in England based on this.

Secondmind is only the first target of Kechuang Bio, and there are several other companies as alternatives.

This was also the first time to travel abroad after the global pandemic. Li Miaomiao took a deep breath after getting off the plane. She was almost suffocating from wearing an N95 mask on the plane.

"Everyone, go over the prepared materials again after arriving at the hotel today to avoid any mistakes tomorrow."

Li Miaomiao specifically asked her to be responsible for this trip to England because she wanted to stop by Singapore on her way back and visit Zheng Li.

"We are a biopharmaceutical company in China and hope to acquire your company. We will not interfere with the normal operations of the company in the first three years after the acquisition."

The reason why Tencent is more popular than Ali in the investment community is that Tencent rarely interferes with the operations of its invested companies, while Ali likes to participate in the operations of its invested companies and replace the senior executives of its invested companies with employees from Ali.

In the investment circle, Ali is much more domineering than Tencent.

"We will only give you advice on AI chips and algorithms."

"The treatment of employees and executives will also remain unchanged."

"This is the information of Kechuang Biotechnology. You can take a look at it."

As a global leader in the field of brain-computer connectivity, Kechuang Biotechnology is very well-known.

Although they may not be able to name the specific company, foreigners will understand it immediately when they mention the Chinese company that specializes in brain-computer connections to mobile phones and endorphins.

Endorphins are as well-known in the biomedical field as brain-computer connections.

After the simultaneous interpreter translated Li Miaomiao's words, the chairman of secondmind nodded: "Okay, I'll take a look first."

The conference room was completely silent, with only the rustling sound of pages turning.

“I don’t deny that Sinovation Biotech is an outstanding company that has made unique contributions in its field.”

"But we are very curious, why would Sinovation Bio want to acquire SecondMind? From the company's information, we have no overlap in our fields."

"SecondMind mainly focuses on AI algorithms and AI chips related to autonomous driving, while Kechuang Biotech seems to be focusing on brain-computer connection in addition to biomedicine."

"I feel like there is very little overlap or complementarity between your company and us."

"So why should we accept your acquisition?"

Li Miaomiao remained calm in the face of the other party's embarrassment:

"SecondMind has not accepted any new investment since its Series B investment in 19. In addition, SecondMind's valuation in Series B investment in 19 was 1 million US dollars, but the actual funds raised were only 2400 million US dollars."

"Due to the impact of the epidemic in the past two years, the price of chip foundry has been rising year by year, and labor costs are also rising. I wonder how long SecondMind can last without investment?"

"Graphcore, also an English AI chip company, received a large amount of funding last year, and DeepMind has been backed by Google since 14."

"How can SecondMind survive? The limited revenue from the cooperation with Mazda cannot support the company's further development."

England is an important place for AI research. Multinational giants have continued to invest in English AI companies over the years, but there are few Chinese companies.

HP announced the acquisition of Autonomy. Amazon acquired True Knowledge. In 2014, Google acquired DeepMind, Dark Blue Labs, Vision Factory, Apple acquired VocalIQ, Microsoft acquired SwiftKey, and Twitter acquired MagicPony.

The following are all companies in the field of artificial intelligence in England, not all of them are AI chips. "We have enough funds, and other investment institutions have expressed their willingness to participate in the C round of investment in SecondMind."

"We will soon advance secondmind's Series C fundraising, and we very much welcome giants like Sinovation Biotech to participate."

They welcome investment, but do not want to be acquired.

Li Miaomiao was very skeptical. No one continued to invest in you in the past two years, but as soon as we said we wanted to acquire you, someone came to invest?
Then she thought again, Cheng Gang had told her when she was on the way that Goldman Sachs and IDG also wanted to participate in the investment in SecondMind.

"Do IDG and Goldman Sachs want to invest in you?"

The other party nodded: "Since you know, I have nothing to hide."

"IDG and Goldman Sachs have signed share transfer memoranda with our shareholders respectively. The two investment institutions have expressed that they will help us start the C round of fundraising as soon as possible."

"IDG and Goldman Sachs will lead the investment."

Li Miaomiao thought that these investment institutions were truly shameless. After knowing that Kechuang Bio was going to acquire SecondMind, they acted much more decisively than they did.

In this regard, Ke Chuang Bio still has many shortcomings. If it were Tencent, it would have completed this task without anyone noticing.

The first meeting ended hastily, and Li Miaomiao felt that she needed to review the specific circumstances of the matter.

Then find out the intentions of IDG and Goldman Sachs.

Currently, the only shareholders of secondmind are Goldman Sachs, IDG, Tencent, Cambridge University Investment Fund and the founder.

The equity structure is simple, but there is no easy win in it.

Kechuang Bio released an announcement at midnight on New Year's Day. The gist of the announcement is:

"Science Biotechnology has completed the research and development of brain-computer connection mobile phones in the English department for all human races. Patents are being registered worldwide, and patent licensing negotiations have been launched simultaneously with major mobile phone manufacturers."

It also states that the licensing price for English-language brain-computer connection patents needs to be adjusted, and it will not be like the Chinese-language patent licensing, which costs 200 RMB per mobile phone.

As soon as the news came out, the top ten science and technology innovation and biological stocks were quickly pushed to the first place:
"Good news has landed, and we are about to dive from a high position!"

There are quite a few such remarks. Not only does the high-level dive make sense, but people in the stock bar have a mentality that if the company releases good news and I don’t hold any positions, then I will just be bearish without thinking.

"The current price of Kechuang Bio is only over 3000 yuan, which is not high. It is expected to reach yuan in the short term."

Currently in the A-share market, Kechuang Bio and Moutai are the only two companies whose stock prices exceed 2,000 yuan.

The stock prices of liquor companies have been rising, so much so that investors jokingly call China's technology stocks "sauce-flavor technology" and "strong-flavor technology."

Most investors would still prefer to see technology stocks represent China's stock market rather than wine companies.

"The patent licensing of the English-language brain-computer interface for mobile phones will generate at least RMB 2022 billion in profits for Kechuang Biotechnology in 60, based on the current patent licensing price.

If the price is renegotiated, net profit will increase further.

Profit is not the most important thing. What is more crucial is that Kechuang Bio was the first to release the announcement, indicating that it is still the strongest company in the field of brain-computer connection.

Kechuang Bio's revenue in the field of brain-computer connection is the sum of the revenues of all other companies in the field of brain-computer connection.

For a company with core monopoly technology that maintains high growth and high profits, why not build a position? "

Tomorrow at 12 o'clock, I will check how many pictures I need to add~ Today the author has a low fever, and I am trying to update you despite the discomfort. I am a serious hand-clumsy person, and I don't like to keep drafts. So I hope everyone will give me a first order for the author to update despite the illness! I'm going to sleep and I'll check the first order tomorrow~


(End of this chapter)